Bukowski R M, Leichman L P, Rivkin S E
Eur J Cancer Clin Oncol. 1983 Jun;19(6):721-3. doi: 10.1016/0277-5379(83)90004-4.
Twenty-three patients with gallbladder and cholangiocarcinoma were treated with m-AMSA at doses of 60-120 mg/m2 i.v. repeated at 4-week intervals. Toxicity was primarily hematologic. Partial responses occurred in 1/12 patients with gallbladder cancer and 1/11 patients with cholangiocarcinoma. The activity of m-AMSA in these neoplasms appears similar to that seen in hepatomas.
